MSF applauds Indian Patent Office’s rejection of Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug
March 23, 2023Mumbai, 23 March 2023 – Today, the 2019 patent challenge by two tuberculosis (TB) survivors, Nandita Venkatesan and Phumeza Tisile, was successful: the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly...
Read more
Between life and living: Patients with drug-resistant tuberculosis (DR-TB) share stories of strength, support and suffering
December 2, 2022India has the highest burden of both tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) based on estimates in the WHO Global TB Report 2022. The country accounts for 28 percent of the global TB burden. In its clinic in Mumbai, MSF...
Read more
endTB trial: First patient enrolls for clinical trials of novel, short and all-oral regimens for multidrug-resistant tuberculosis in India
October 22, 2020Pune, India: Doctors Without Borders/ Médecins Sans Frontières (MSF) in collaboration with Indian Council for Medical Research (ICMR)- National AIDS Research Institute (NARI) and Department of Health Service, Government of Maharashtra is initiating two major clinical trials that aim at generating clinical evidence...
Read more
Providing medical care for drug-resistant tuberculosis in Mumbai
February 12, 2019MSF in South Asia: Projects in South Asia Access campaign Connect with us What We Do MSF provides free, comprehensive and individualized treatment at its independent clinic in Mumbai to people with severe forms of Drug resistant Tuberculosis (DRTB). Patients seen by...
Read more
Renewed hope- Stories of four patients fighting drug-resistant-TB in Mumbai
March 24, 2018Name : Designation : Interviews conducted & written by DVL Padma Priya for MSF For World TB Day 2018, we celebrate the courage and endurance of four MSF patients who are currently undergoing treatment for drug-resistant TB (DR-TB). Pooja,...
Read more
India: Renewed hope with new drugs
October 28, 2016Two new drugs, bedaquiline and delamanid, are proving to be the very last lifeline for tuberculosis (TB) patients with the most extreme forms of drug resistance. While a few patients benefit from these new drugs in India, many die before being able...
Read more
